
NSAIDS are typically the first line of treatment for axial spondyloarthritis.

NSAIDS are typically the first line of treatment for axial spondyloarthritis.

Chronic pain is more prevalent—and more severe—in veterans compared with the general US population.

Research presented at American Heart Association’s 2024 Scientific Sessions examined the SGLT inhibitor’s effect on systolic blood pressure.

Investigators evaluated the role that cannabis plays in pain management in different populations with rheumatic diseases.

Premenstrual Dysphoric Disorder is considered a psychiatric disorder and is associated with moderate to severe physical, affective, and behavioral symptoms.

“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.

The Mediterranean diet is largely considered one of the healthiest diets.

Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.

Three research posters presented at the American Heart Association’s 2024 Scientific Sessions looked into the use of SGLT-2 inhibitors in patients with type 2 diabetes and cardiovascular complications.

Patients with type 2 diabetes who had eating problems and higher levels of diabetes distress had worse time-in-range.

A conversation with Trent Thiede, PharmD, MBA, president of PAAS National, at NCPA 2024.

Pharmacy experts from AON Pharmacy in Florida discussed the Inflation Reduction Act and how it affects reimbursement for Medicare Part D drugs.

A conversation with AJ Loiacono, co-founder and CEO of Capital RX, at NCPA 2024.

Selina Coleman, JD, Partner in Life Sciences Health Industry Group at Reed Smith LLP, discussed recent developments in Supreme Court decisions impacting pharmacy operations.

An FDA representative gave a presentation on her organization’s recent updates regarding drug supply chain rules and regulations.

Pharmacy law experts detailed the Drug Supply Chain Security Act, highlighting the role each entity within the supply chain plays in ensuring the safety and authenticity of US prescription drugs.

FDA experts gathered to discuss the DEA’s rescheduling of marijuana and how it will impact the pharmaceutical supply chain.

Stephen Schondelmeyer, PharmD, PhD, FAPhA, gave a presentation on US drug shortages and their global implications.

Joel Ferre, JD, Assistant United States Attorney in Utah, led a discussion covering the DEA and pharmacies’ roles in reporting red flags when dispensing medication.

Checkout some of the most important sessions and video interviews from the 2024 National Community Pharmacists Association (NCPA) Annual Convention and Expo.

Erin Rexroth, director of marketing at NCPA, discusses how smaller pharmacies can compete with large chains when it comes to digital marketing.

A conversation with Lauren Angelo, PharmD, MBA, associate dean of academic affairs and an associate professor of pharmacy practice at Rosalind Franklin University of Medicine and Science College of Pharmacy.

A conversation with Melody Hartzler, PharmD, at the 2024 National Community Pharmacists Association Annual Convention and Expo.

Presenters at the National Community Pharmacists Association 2024 Annual Convention and Expo discussed workflow and the future of pharmacy as a patient destination.

A conversation with David Ha, PharmD, BCIDP, at the National Community Pharmacists Association 2024 Annual Convention and Expo.

Trent Thiede, PharmD, MBA, president of PAAS National, discusses best practices that pharmacy teams can implement to proactively prevent audit issues before they arise.

At the NCPA 2024 Annual Convention and Expo, Drug Topics asked different pharmacists what they think the importance of the conference is to the independent pharmacy community.

Melody Hartzler, PharmD, discusses common metabolic roadblocks to weight loss and what tools pharmacy teams can use to identify and address them.

A conversation with Sean Jeffery, PharmD, BCGP, FASCP, AGSF, director of pharmacy at Hartford HealthCare Integrated Care Partners and professor of pharmacy practice at the University of Connecticut.